About Coherus Biosciences
Coherus Biosciences is a clinical stage, pure-play biosimilar company headquartered in the San Francisco Bay Area. The company was founded by a group of biotech pioneers brought together by the shared vision of using their expertise and knowledge to increase global patient access to high quality, life changing biologic medications. From conceptualization to commercialization, Coherus’ unique business model leverages a strategic consortium of key service providers aligned through ownership and shared incentives. Coherus’ global partnerships include top-tier Biopharma in Europe, Asia, and Latin America pursuing the integrated development and commercialization of products representing over $35 billion in current sales. For additional information, please visit www.coherus.com.
This release includes forward-looking statements concerning a development and commercialization agreement between Baxter International Inc. and Coherus Biosciences, Inc., including expectations with regard to future milestone payments. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; clinical trial results; changes in laws and regulations; product quality or patient safety issues; and other risks identified in Baxter's most recent filings on Form 10-K and other SEC filings. Baxter does not undertake to update its forward-looking statements.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts